IONIS PHARMACEUTICALS INC — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Roche's Phase 3 IMAgINATION study of sefaxersen (licensed from Ionis) met its primary endpoint, demonstrating statistically significant proteinuria reduction versus placebo at 37 weeks in 459 patients with IgA nephropathy. The study continues blinded to week 105 to assess kidney function preservation (eGFR); interim data will be presented at medical congresses and shared with regulators. Under the Roche license agreement, Ionis receives upfront, milestone, and royalty payments—specific amounts not disclosed in this filing.
Why this rating
Positive Phase 3 interim data substantially de-risks a major partnered program (Roche-licensed asset) in kidney disease. Milestone and royalty upside material to ~$5.3B market cap; advances path to regulatory approval and commercial launch in large unmet-need market.
Price action (we called it positive)
before filing · preread $47.29 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.